Abstract
The phosphatidylinositol 3'-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway contributes to prostate cancer progression and transition to androgen-independent disease. Furthermore, recent microarray analysis demonstrates that this pathway is often deregulated during prostate cancer progression. Thus, targeting of PI3K/AKT/mTOR may present a promising therapy for castration-refractory prostate cancer (CRPC). In recent years, several interesting strategies have been developed that interfere with distinct components of the PI3K/AKT/mTOR cascade. This article discusses many of the mechanisms involved, specifically in the context of prostate cancer. In addition, we present an overview of preliminary data on the activity of mTOR inhibitors and on the key steps to evaluate which of these compounds are most suitable for the treatment of prostate cancer. Particular emphasis is also placed on the development of novel perspectives to improve the poor prognosis of patients with CRPC.
Keywords: AKT, hypoxia, mTOR, PI3K, prostate cancer, signaling, therapy
Current Cancer Drug Targets
Title:Perspectives on mTOR Inhibitors for Castration-Refractory Prostate Cancer
Volume: 12 Issue: 8
Author(s): Salvatore L. Burgio, Francesco Fabbri, Ian J. Seymour, Wainer Zoli, Dino Amadori and Ugo De Giorgi
Affiliation:
Keywords: AKT, hypoxia, mTOR, PI3K, prostate cancer, signaling, therapy
Abstract: The phosphatidylinositol 3'-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway contributes to prostate cancer progression and transition to androgen-independent disease. Furthermore, recent microarray analysis demonstrates that this pathway is often deregulated during prostate cancer progression. Thus, targeting of PI3K/AKT/mTOR may present a promising therapy for castration-refractory prostate cancer (CRPC). In recent years, several interesting strategies have been developed that interfere with distinct components of the PI3K/AKT/mTOR cascade. This article discusses many of the mechanisms involved, specifically in the context of prostate cancer. In addition, we present an overview of preliminary data on the activity of mTOR inhibitors and on the key steps to evaluate which of these compounds are most suitable for the treatment of prostate cancer. Particular emphasis is also placed on the development of novel perspectives to improve the poor prognosis of patients with CRPC.
Export Options
About this article
Cite this article as:
L. Burgio Salvatore, Fabbri Francesco, J. Seymour Ian, Zoli Wainer, Amadori Dino and De Giorgi Ugo, Perspectives on mTOR Inhibitors for Castration-Refractory Prostate Cancer, Current Cancer Drug Targets 2012; 12 (8) . https://dx.doi.org/10.2174/156800912803251234
DOI https://dx.doi.org/10.2174/156800912803251234 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeted Radionuclide Therapy of Painful Bone Metastases: Past Developments, Current Status, Recent Advances and Future Directions
Current Medicinal Chemistry Glycogen Synthase Kinase-β3 in Ischemic Neuronal Death
Current Neurovascular Research A Review on Designing Poly (Lactic-co-glycolic Acid) Nanoparticles as Drug Delivery Systems
Pharmaceutical Nanotechnology Interrelationships Among Gut Microbiota and Host: Paradigms, Role in Neurodegenerative Diseases and Future Prospects
CNS & Neurological Disorders - Drug Targets Prospective Teratology of Retinoic Acid Metabolic Blocking Agents (RAMBAs) and Loss of CYP26 Activity
Current Pharmaceutical Design Establishment of Conditionally Immortalized Cell Lines with Specific Functions and its Application to Differential Gene Expression Analysis by DNA Microarray Technology
Current Pharmaceutical Analysis Cellomics as Integrative Omics for Cancer
Current Proteomics Kinase Inhibitors in Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Wnt Signaling and Prostate Cancer
Current Drug Targets V. Amygdalina: Folk Medicine, Analysis, and Potential Application for Cancer Treatment
Current Pharmaceutical Analysis Therapeutic Polycomb Targeting in Human Cancer
Recent Patents on Regenerative Medicine Targeting Hormonal Signaling Pathways in Castration Resistant Prostate Cancer
Recent Patents on Anti-Cancer Drug Discovery Recent Progress in Phosphoinositide 3-Kinases: Oncogenic Properties and Prognostic and Therapeutic Implications
Current Protein & Peptide Science Penile Rehabilitation After Radical Prostatectomy
Current Drug Targets Immune Checkpoint Inhibitors for Non-small-cell Lung Cancer: Does that Represent a ‘New Frontier’?
Anti-Cancer Agents in Medicinal Chemistry Epigenetic and Disease Targets by Polyphenols
Current Pharmaceutical Design Molecular Biological Roles of Ursolic Acid in the Treatment of Human Diseases
Current Bioactive Compounds Gallium in Cancer Treatment
Current Topics in Medicinal Chemistry Targeting Transcription Factors for Cancer Gene Therapy
Current Gene Therapy Targeting Hsp90 in Non-Cancerous Maladies
Current Topics in Medicinal Chemistry